{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:55:32Z","timestamp":1789210532105,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Yellow fever vaccine 17D has controlled yellow fever for almost 90 years and is considered highly successful. However, with recent outbreaks in South America and Africa, yellow fever continues to represent a significant threat to public and global health. Despite the long-standing success, few studies have characterized the capacity of 17D-immune sera to neutralize wild type (WT) yellow fever viruses (YFVs).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using 17D and 13 WT YFVs, we conducted focus neutralization tests against sera from a unique cohort of 36 nonendemic vaccinees with diverse Orthoflavivirus histories. By using WT YFVs that represent the known YFV genotypes, we characterized the potency and breadth of 17D-elicited serum neutralizing antibodies against these WT YFVs in the context of heterologous Orthoflavivirus infection.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We found significant variability in neutralization test titers and rates of seropositivity of 17D-immune sera across all viruses and specifically against South America genotype I isolates. Vaccinee sera with serologic evidence of heterologous Orthoflavivirus infection had significantly greater potency against South America genotype I strains as compared with sera without evidence of Orthoflavivirus infection, suggesting a boosting effect from heterologous Orthoflavivirus immunity.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These results add significantly to what is known regarding the WT YFV antigenic immune landscape, including novel insights into the role of heterologous Orthoflavivirus infection in 17D immunity that have the potential to improve future vaccine design and deployment strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/infdis\/jiag077","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:30:15Z","timestamp":1770726615000},"page":"e232-e242","source":"Crossref","is-referenced-by-count":4,"title":["New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous\n Orthoflavivirus<\/i>\n Infection"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-8752","authenticated-orcid":false,"given":"Felicity J","family":"Coulter","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0963-298X","authenticated-orcid":false,"given":"Courtney A","family":"Micheletti","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-7762","authenticated-orcid":false,"given":"Abram E","family":"Estrada","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5608-7167","authenticated-orcid":false,"given":"Shuhua","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-3869","authenticated-orcid":false,"given":"Samantha R","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4260-055X","authenticated-orcid":false,"given":"Chad D","family":"Nix","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Y","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7868-1673","authenticated-orcid":false,"given":"Sarah M","family":"Sampouw","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettie W","family":"Kareko","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-6347","authenticated-orcid":false,"given":"William B","family":"Messer","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]},{"name":"Oregon Health & Science University\u2013Portland State University School of Public Health Program in Epidemiology, , Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026090212222226000_jiag077-B1","doi-asserted-by":"crossref","first-page":"e64670","DOI":"10.7554\/eLife.64670","article-title":"The global burden of yellow fever","volume":"10","author":"Gaythorpe","year":"2021","journal-title":"Elife"},{"key":"2026090212222226000_jiag077-B2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/am.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"2026090212222226000_jiag077-B3","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"2026090212222226000_jiag077-B4","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/cid\/ciac580","article-title":"Duration of protection after vaccination against yellow fever: a systematic review and meta-analysis","volume":"75","author":"Kling","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026090212222226000_jiag077-B5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2021.12.029","article-title":"Exploratory study of humoral and cellular immunity to 17DD yellow fever vaccination in children and adults residents of areas without circulation of yellow fever virus","volume":"40","author":"Reis","year":"2022","journal-title":"Vaccine"},{"key":"2026090212222226000_jiag077-B6","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"key":"2026090212222226000_jiag077-B7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health"},{"key":"2026090212222226000_jiag077-B8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J Med Virol"},{"key":"2026090212222226000_jiag077-B9","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1128\/JVI.75.15.6999-7008.2001","article-title":"Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa","volume":"75","author":"Mutebi","year":"2001","journal-title":"J Virol"},{"key":"2026090212222226000_jiag077-B10","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1371\/journal.ppat.0030075","article-title":"Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas","volume":"3","author":"Bryant","year":"2007","journal-title":"PLoS Pathog"},{"key":"2026090212222226000_jiag077-B11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.chom.2021.12.009","article-title":"Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies","volume":"30","author":"Haslwanter","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2026090212222226000_jiag077-B12","doi-asserted-by":"crossref","first-page":"e0370323","DOI":"10.1128\/spectrum.03703-23","article-title":"Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017\u20132018 sylvatic outbreak in Brazil","volume":"12","author":"Goncalves","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026090212222226000_jiag077-B13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/infdis\/jiz374","article-title":"Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting","volume":"221","author":"Kareko","year":"2019","journal-title":"J Infect Dis"},{"key":"2026090212222226000_jiag077-B14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/molbev\/msz312","article-title":"Molecular evolutionary genetics analysis (MEGA) for macOS","volume":"37","author":"Stecher","year":"2020","journal-title":"Mol Biol Evol"},{"key":"2026090212222226000_jiag077-B15","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"MEGA11: molecular evolutionary genetics analysis version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol Biol Evol"},{"key":"2026090212222226000_jiag077-B16","first-page":"353","volume-title":"Atlas of protein sequences","author":"Schwarz","year":"1979"},{"key":"2026090212222226000_jiag077-B17","doi-asserted-by":"crossref","first-page":"e0008006","DOI":"10.1371\/journal.pntd.0008006","article-title":"Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype","volume":"14","author":"Nix","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2026090212222226000_jiag077-B18","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"Dengue viruses cluster antigenically but not as discrete serotypes","volume":"349","author":"Katzelnick","year":"2015","journal-title":"Science"},{"key":"2026090212222226000_jiag077-B19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"2026090212222226000_jiag077-B20","first-page":"pdb.top38","article-title":"Using PAM matrices in sequence alignments","volume":"2008","author":"Mount","year":"2008","journal-title":"CSH Protoc"},{"key":"2026090212222226000_jiag077-B21","doi-asserted-by":"crossref","first-page":"eadk3259","DOI":"10.1126\/scitranslmed.adk3259","article-title":"Antigenic distance between primary and secondary dengue infections correlates with disease risk","volume":"16","author":"Wang","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026090212222226000_jiag077-B22","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.chom.2022.10.012","article-title":"Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history","volume":"30","author":"Wang","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2026090212222226000_jiag077-B23","author":"Wilks"},{"key":"2026090212222226000_jiag077-B24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/am.16.11.1770-1775.1968","article-title":"Yellow fever virus: I. Development and evaluation of a plaque neutralization test","volume":"16","author":"Spector","year":"1968","journal-title":"Appl Microbiol"},{"key":"2026090212222226000_jiag077-B25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/am.23.5.908-913.1972","article-title":"Yellow fever vaccine: V. Antibody response in monkeys inoculated with graded doses of the 17D vaccine","volume":"23","author":"Mason","year":"1972","journal-title":"Appl Microbiol"},{"key":"2026090212222226000_jiag077-B26","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090212222226000_jiag077-B27","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1038\/s41467-024-54146-9","article-title":"Potential role of heterologous flavivirus immunity in preventing urban transmission of yellow fever virus","volume":"15","author":"Shinde","year":"2024","journal-title":"Nat Commun"},{"key":"2026090212222226000_jiag077-B28","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1073\/pnas.1500475112","article-title":"Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination","volume":"112","author":"Akondy","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090212222226000_jiag077-B29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","article-title":"Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans","volume":"10","author":"Kalimuddin","year":"2025","journal-title":"Nat Microbiol"},{"key":"2026090212222226000_jiag077-B30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine"},{"key":"2026090212222226000_jiag077-B31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity\u2014effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"2026090212222226000_jiag077-B32","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2026090212222226000_jiag077-B33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2005.11.042","article-title":"Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN","volume":"124","author":"Pokidysheva","year":"2006","journal-title":"Cell"},{"key":"2026090212222226000_jiag077-B34","doi-asserted-by":"crossref","first-page":"e00104-20","DOI":"10.1128\/JVI.00104-20","article-title":"Flavivirus envelope protein glycosylation: impacts on viral infection and pathogenesis","volume":"94","author":"Carbaugh","year":"2020","journal-title":"J Virol"},{"key":"2026090212222226000_jiag077-B35","first-page":"310","article-title":"Prediction of glycosylation across the human proteome and the correlation to protein function","author":"Gupta","year":"2002","journal-title":"Pac Symp Biocomput"},{"key":"2026090212222226000_jiag077-B36","doi-asserted-by":"crossref","first-page":"126423","DOI":"10.1016\/j.vaccine.2024.126423","article-title":"Breakthroughs and insights: a comprehensive review of yellow fever vaccine breakthrough infection across 8 decades","volume":"43","author":"Coulter","year":"2025","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag077\/66850198\/jiag077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/e232\/66850198\/jiag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/e232\/66850198\/jiag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:22:31Z","timestamp":1788366151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/2\/e232\/8472523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag077","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,2,11]]}}}